First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Main Inclusion Criteria: * Histologically or cytologically confirmed relapsed/refractory hematological malignancy or advanced/metastatic solid cancer * Measurable disease * Have had all available therapeutic standards for their disease * Willingness to undergo baseline biopsy/bone marrow aspiration in case biopsy was not collected after completion of the most recent prior therapy * ECOG performance status ≤ 1 * Life expectancy \> 3 months as assessed by the investigator * Acceptable clinical lab results Main Exclusion Criteria: * Systemic steroids at a daily dose of \> 10 mg of prednisone or equivalent within 28 days before study treatment. Transient use of steroids for other medical condition may be allowed * Ongoing immune-related adverse events irAEs and or AEs ≥ grade 2 from previous therapies not resolved except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with substitutive hormone therapy * Within 4 weeks of major surgery * Documented history of active autoimmune disorder requiring systemic immunosuppressive therapy within the last 12 months * Prior solid organ transplant * Primary or secondary immune deficiency * Active and uncontrolled infection requiring intravenous antibiotic or antiviral treatment * Seropositive (except after vaccination or confirmed cure for hepatitis) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) * Clinically significant disease